The statistical control for OPRM1 A118G genotype in all models represented a significant strength of this study, and doing so did not diminish the significance of the novel pharmacogenetic effects reported. Second, this trial of naltrexone was double-blinded, placebo-controlled, and consisted of a crossover design such that all participants received both naltrexone and placebo, enhancing the reliability and power of our findings. Third, alcohol was administered intravenously rather than orally, which resulted in tightly controlled blood alcohol concentrations. Lastly, a proper p-value correction for multiple comparisons was implemented, reducing the likelihood of false positives in this exploratory analysis.
